Epidemiological profile and predictors of mortality in acute coronary syndrome: a prospective study

Madhavi Sarkari, Mukesh Jaiswal


Background: India has shown a rising trend in the prevalence of coronary artery disease (CAD) in urban as well as in rural population. Acute coronary syndrome (ACS) is the main reason for the mortality in India. Study of risk factors and biomarkers is important to catch the diagnosis early in order to decrease the mortality. Objective was to study risk factors and brain natriuretic peptide (BNP), troponine I, and CKMB and their effect on outcome in ACS patients in tertiary hospital.

Methods: One hundred and fifty ACS patients were studied in Emergency Department of Medicine, Nehru Hospital, BRD Medical College, Gorakhpur from January 2017 to December 2017. Data on age sex socioeconomic status, medical history, baseline clinical characteristics, time to reach hospital and treatment in hospital, along with biomarkers including BNP, Troponin Iand CKMB was estimated. Baseline ECG was obtained at admission and repeated at 12 -24 hours and every 24 hours thereafter. A 2D Echocardiogram was performed within initial 48-72 hours for analysis of LVEF and wall motion abnormalities.

Results: Male (58.7%) preponderance was observed with mean age of 60.12±10.58 years. Most of the patients were from rural areas (87.3%) and had hypertension (44.7%). Chest pain was most common symptom (56%). Most of them had duration of symptoms for 6-12 hours (56%). NSTEMI, STEMI and unstable angina were equally distributed between the genders (p>0.05). Out of 150 patients, 15 (10%) were thrombolysed, 78.52% had RWMA. In-hospital mortality was higher; among the patients of age >75 years (38.5%) (p=0.008), male patient (12.5%) (p>0.05), rural patient (10.7%) (p>0.05), hypertensive patient (17.3%) (p>0.05), patients of Killip class IV (48.3%)(p=0.0001) and patients having severe LVD (33.3%) (p=0.0001). In-hospital mortality was 1.2% and 1.1% among those in whom beta blocker and ACE inhibitors was present (p>0.0001). BNP and CKMB was significantly higher among expired patients (1762.62±1444.89 vs 840.76±1294.82; p=0.001) similarly troponin I was significantly higher among expired patients (67.29±45.63 vs 43.99±41.73; p=0.006) than alive.

Conclusions: ACS was more prevalent in male, living in fifth to sixth decade of life, had hypertension. STEMI was more common. Patients on ACE inhibitors and beta-blocker had better outcome. Mortality was higher in patients with Killip’s class IV, higher value of troponin I, age more than 75 years and had hypertension and dyslipidemia.


Acute coronary syndrome, Biomarkers, In-hospital mortality, Killip class, NSTEMI, STEMI

Full Text:



Murray CJL, lopez AD. Mortality by cause for eight regions of the world: Global Burden of disease study. Lancet. 1997;349:1269-76.

Reddy KS. Cardiovascular diseases in India. World Health Stat Q. 1993;46:101-7.

Sabatine MS, Morrow DA, de Lemos JA. Multimarker approach to risk stratification in non-ST-elevation acute coronary syndromes. Circulation. 2002;105:1760-3.

Pearson TA, Mensah G, Alexander RW. AHA/CDC scientific statement-markers of inflammation and cardiovascular disease. Circulation. 2003;107:499-51.

Misiriya R, Sudhayakumar N. The Clinical Spectrum of Acute Coro Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.

Mishra D, Singh H.P. Kuppuswamy’s socio-economic status scale – a revision. Indian J Paediatr. 2003;70:273-4.

Lakoski SG, Cushman M, Criqui M. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152:593-8.

Aguilar D, Fisher MR, O’ Connor CM. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J. 2006;152:298-304.

Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.

Berk BC, Weintraub WS, Alexander RW. Elevation of biomarker protein in "active" coronary artery disease. Am J Cardiol. 1990;65:168-72.

Rastogi T, Vaz M, Spiegelman D, Reddy KS, Bharathi AV, Stampfer MJ, et al. Physical activity and risk of coronary heart disease in India. Int J Epidemiol. 2004;33:759-67.

Santos AC, Lopes C, Guimaraes JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes. 2005;29:1452-6.

McLaughlin T, Abbasi F, Lamendola C. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106:2908-12.

Han T, Sattar N, Williams K, Gonzalez-Villalpando C, Lean M, Haffner S. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25:2016-21.

Albert MA, Danielson E, Rifai N. Effect of statin therapy on C-reactive protein levels. JAMA. 2001;286:64-70.

Hasdai D, Behar S, Wallentin L. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002;23:1190-01.

Emad A, Rajvir S, Ayman EM. Effect of age on clinical presentation and outcome of patients hospitalized with acute coronary syndrome: A 20-Year Registry in a Middle Eastern Country. Open Cardiovasc Med J. 2012;6(1):60-7.

Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndromes: prospective multinational observational study (GRACE) BMJ. 2006;333(7578):1091-4.

Goldberg RJ, Currie K, White K, Brieger D, Steg PG, Goodman SG et al. Six-months outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (GRACE). Am J Cardiol. 2004;93:288-93.

Misiriya R, Sudhayakumar N. The clinical spectrum of acute coronary syndromes. JAPI. 2009;57(377):6-9.

Henrique BP, Adriano C. Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction undergoing pharmacoinvasive treatment. PMCID. 2013;68(12):1516-20.

Riegel B, Hanlon AL. Differences in mortality in acute coronary syndrome symptom clusters. Am Heart J. 2010;159(3):392-8.

Brezinov PO, Klempfner R. Prognostic value of ejection fraction in patients admitted with acute coronary syndrome. PMCID. 2017:4-8.

Widimsky P. An article from the e-journal of the ESC Council for Cardiology Practice. Eur Soc Cardiol. 2007;5(3):40-7.